Form 10-Q

0001513162-18-000062.txt : 20180309 0001513162-18-000062.hdr.sgml : 20180309 20180308173259 ACCESSION NUMBER: 0001513162-18-000062 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20171201 FILED AS OF DATE: 20180309 DATE AS OF CHANGE: 20180308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ITUS Corp CENTRAL INDEX KEY: 0000715446 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 112622630 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37492 FILM NUMBER: 18677566 BUSINESS ADDRESS: STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250 CITY: SAN JOSE STATE: CA ZIP: 95118 BUSINESS PHONE: 310-484-5200 MAIL ADDRESS: STREET 1: 3150 ALMADEN EXPRESSWAY, SUITE 250 CITY: SAN JOSE STATE: CA ZIP: 95118 FORMER COMPANY: FORMER CONFORMED NAME: COPYTELE INC DATE OF NAME CHANGE: 19920703 10-Q 1 form10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2018

Commission file number 0-11254

ITUS Corporation

(Exact name of registrant as specified in its charter)

Delaware 11-2622630

(State or other jurisdiction of (I.R.S. Employer

incorporation or organization) Identification No.)

3150 Almaden Expressway, Suite 250

San Jose, CA 95118

(Address of principal executive offices) (Zip Code)

(408) 708-9808

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X No ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)		Smaller reporting company [X]
Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ____ No X

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

On March 5, 2018, the registrant had outstanding 16,631,191 shares of Common Stock, par value $.01 per share, which is the registrant’s only class of common stock.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements.

	Condensed Consolidated Balance Sheets as of January 31, 2018 (Unaudited) and October 31, 2017	3

	Condensed Consolidated Statements of Operations (Unaudited) for the three months ended January 31, 2018 and 2017	4

	Condensed Consolidated Statement of Shareholders’ Equity (Unaudited) for the three months ended January 31, 2018	5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended January 31, 2018 and 2017	6

	Notes to Condensed Consolidated Financial Statements (Unaudited)	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	23

Item 4.	Controls and Procedures.	23

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings.	25

Item 1A.	Risk Factors.	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	25

Item 3.	Defaults Upon Senior Securities.	25

Item 4.	Mine Safety Disclosures.	25

Item 5.	Other Information.	25

Item 6.	Exhibits.	25

SIGNATURES		26

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

	(Unaudited)
	January 31, 2018		October 31, 2017
ASSETS	January 31, 2018		October 31, 2017
Current assets:
Cash and cash equivalents	$	2,846,863	$	3,339,374
Short-term investments in certificates of deposit		2,650,000		3,500,000
Prepaid expenses and other current assets		278,496		174,566
Total current assets		5,775,359		7,013,940

Patents, net of accumulated amortization of $1,371,660 and $1,290,336, respectively		1,664,451		1,745,775
Property and equipment, net of accumulated depreciation of $39,756 and $35,725, respectively		50,828		52,701
Total assets	$	7,490,638	$	8,812,416

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	416,925	$	480,324
Accrued expenses		669,633		409,169
Total current liabilities		1,086,558		889,493

Commitments and contingencies (Note 10)

Equity:
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding		-		-
Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding		-		-
Common stock, par value $.01 per share; 24,000,000 shares authorized; 16,631,191 and 16,602,759 shares issued and outstanding, respectively		166,312		166,028
Additional paid-in capital		164,281,744		163,931,079
Accumulated deficit		(158,012,256)		(156,174,184)
Total shareholders’ equity		6,435,800		7,922,923
Noncontrolling interest (Note 1)		(31,720)		-
Total equity		6,404,080		7,922,923

Total liabilities and equity	$	7,490,638	$	8,812,416

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	For the Three Months Ended January 31,
	For the Three Months Ended January 31,
	2018		2017
Revenue	$	-	$	-

Operating costs and expenses:
Inventor royalties, contingent legal fees and litigation and licensing expenses related to patent assertion		25,353		2,121
Amortization of patents		81,324		81,324
Research and development expenses (including non-cash stock option compensation expense of $40,057 and $79,700, respectively)		777,873		451,630
General and administrative expenses (including non-cash stock option compensation expense of $226,916 and $180,037 respectively)		990,036		859,885
Total operating costs and expenses		1,874,586		1,394,960

Loss from operations		(1,874,586)		(1,394,960)

Interest expense		-		(195,299)

Interest income		9,112		999

Loss before income taxes		(1,865,474)		(1,589,260)

Provision for income taxes		-		-

Net loss		(1,865,474)		(1,589,260)

Less: Net loss attributable to noncontrolling interest		(27,402)		-

Net loss attributable to common shareholders before deemed dividend		(1,838,072)		(1,589,260)

Deemed dividend to preferred shareholder (Note 6)		-		(2,008,775)

Net loss attributable to common shareholders	$	(1,838,072)	$	(3,598,035)

Net loss per share attributable to common shareholders:
Basic and diluted	$	(0.11)	$	(0.41)

Weighted average common shares outstanding:
Basic and diluted		16,610,770		8,755,057

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY FOR THE THREE MONTHS ENDED JANUARY 31, 2018 (UNAUDITED)

				Additional Paid-in Capital				Total Shareholders’ Equity		Non- controlling Interest
	Common Stock					Accumulated Deficit						Total Equity
	Shares	Par Value				Accumulated Deficit						Total Equity

Balance, October 31, 2017	16,602,759	$	166,028	$	163,931,079	$	(156,174,184)	$	7,922,923	$	-	$	7,922,923

Stock option compensation to employees and directors	-		-		214,427		-		214,427		-		214,427

Stock option compensation to consultants	-		-		52,546		-		52,546		-		52,546

Common stock issued upon exercise of stock options	23,085		231		(231)		-		-		-		-

Common stock issued to consultants	5,347		53		14,949		-		15,002		-		15,002

Issuance of noncontrolling interest in Certainty Therapeutics, Inc	-		-		68,974		-		68,974		(4,318)		64,656

Net loss	-		-		-		(1,838,072)		(1,838,072)		(27,402)		(1,865,474)

Balance, January 31, 2018	16,631,191	$	166,312	$	164,281,744	$	(158,012,256)	$	6,435,800	$	(31,720)	$	6,404,080

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the three months ended January 31,
	2018		2017
Reconciliation of net loss to net cash used in operating activities:
Net loss	$	(1,865,474)	$	(1,589,260)
Stock option compensation to employees and directors		214,427		259,737
Stock option compensation to consultants		52,546		-
Common stock issued to consultants		15,002		17,811
Depreciation of property and equipment		4,391		10,505
Amortization of patents		81,324		81,324
Accretion of interest on patent acquisition obligations to interest expense		-		141,299
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee		64,656		-
Change in operating assets and liabilities:
Prepaid expenses and other current assets		(103,930)		93,480
Accounts payable		(63,399)		167,453
Accrued expenses		260,464		87,738
Net cash used in operating activities		(1,339,993)		(729,913)

Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit		(1,250,000)		-
Proceeds from maturities of short-term investments in certificates of deposit		2,100,000		150,000
Purchase of property and equipment		(2,518)		(14,121)
Net cash provided by investing activities		847,482		135,879

Cash flows from financing activities:
Redemption of convertible preferred stock		-		(500,000)
Proceeds from exercise of employee stock options		-		5,665
Net cash used in by financing activities		-		(494,335)

Net decrease in cash and cash equivalents		(492,511)		(1,088,369)
Cash and cash equivalents at beginning of period		3,339,374		2,488,323
Cash and cash equivalents at end of period	$	2,846,863	$	1,399,954

Supplemental disclosure of non-cash financing activities:
Redemption of Series A convertible preferred stock into secured debenture (Note 6)	$	-	$	(3,000,000)

The accompanying notes are an integral part of these statements.

Table of Contents

ITUS CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. BUSINESS AND FUNDING

Description of Business

As used herein, “we,” “us,” “our,” the “Company” or “ITUS” means ITUS Corporation and its wholly-owned subsidiaries. From inception through October 2012, our primary operations involved the development of patented technologies in the areas of thin-film displays and encryption. Commencing in October 2012 the primary operations of the Company involved the development, acquisition, licensing, and enforcement of patented technologies that were either owned or controlled by the Company.

In June of 2015, the Company announced the formation of a new subsidiary, Anixa Diagnostics Corporation (“Anixa”), to develop a platform for non-invasive blood tests for the early detection of cancer. That platform is called CchekÔ . In July of 2015, ITUS announced a collaborative research agreement with The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading National Cancer Institute designated cancer research center, for the purpose of validating our cancer detection methodologies and establishing protocols for identifying certain biomarkers in the blood which we identified and which are known to be associated with malignancies. In August of 2016 and again in August of 2017, ITUS announced the renewal and expansion of our relationship with Wistar.

From October of 2015 through January of 2017, ITUS announced that we had demonstrated the efficacy of our CchekÔ early cancer detection platform with 15 different types of cancer, including: breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar and prostate. Breast, lung, colon and prostate cancers represent the four largest categories of cancer worldwide.

In November of 2017, the Company announced the formation of a new subsidiary, Certainty Therapeutics, Inc. (“Certainty”), to develop immuno-therapy drugs against cancer. Certainty entered into a license agreement with Wistar pursuant to which Certainty was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Wistar relating to Wistar’s chimeric endocrine receptor targeted therapy technology (such technology being akin to chimeric antigen receptor T-cell (“CAR-T”) technology). We plan to initially focus on the development of a treatment for ovarian cancer, but we also may pursue future applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common stock of Certainty.

Table of Contents

On November 20, 2017, we announced that Certainty entered into a collaboration agreement with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”) to advance toward human clinical testing the CAR-T technology licensed by Certainty from Wistar aimed initially at treating ovarian cancer. Certainty intends to work with researchers at Moffitt to complete studies necessary to submit an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”).

On January 29, 2018, we announced the results of a study augmenting data from our preliminary study released in December 2016. The majority of patient samples collected for this study were from breast cancer and prostate cancer patients, but several other types were also included. With the additional cancers included in this study, we have now demonstrated our technology with 20 types of cancer from solid tumors. In addition to the 15 cancer types noted above, we have evaluated bladder, cervical, head and neck, gastric and testicular cancers.

Over the next several quarters, we expect Cchek™ and Certainty’s ovarian cancer treatment to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management.

Over the past several quarters, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. In addition to Anixa and Certainty, the Company may make investments in and form new companies to develop additional emerging technologies.

Funding and Management’s Plans

During the three months ended January 31, 2018, cash used in operating activities was approximately $1,340,000. Net cash provided by investing activities was approximately $847,000, which reflects the purchase of certificates of deposit totaling $1,250,000, offset by proceeds from the sale or maturity of certificates of deposit totaling $2,100,000 and the purchase of property and equipment of approximately $3,000. As a result, our cash, cash equivalents and short-term investments at January 31, 2018 decreased by approximately $1,342,000 to approximately $5,497,000 from approximately $6,839,000 at the end of fiscal year 2017.

Based on currently available information as of March 8, 2018, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next 12 months. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies that are synergistic with or complimentary to our technologies, we may be required to obtain more working capital. We may seek to obtain working capital during our fiscal year ending 2018 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our shareholders. Additionally, the sale of equity securities or issuance of debt securities may be subject to certain security holder approvals or may result in the downward adjustment of the exercise or conversion price of our outstanding securities. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations.

Table of Contents

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2017. The accompanying October 31, 2017 consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (“US GAAP”). The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of January 31, 2018, and results of operations and cash flows for the interim periods represented. The results of operations for the three months ended January 31, 2018 are not necessarily indicative of the results to be expected for the entire year.

Noncontrolling Interest

Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2018:

Balance October 31, 2017	$	0
Issuance of noncontrolling interest in Certainty		(4,318)
Net loss attributable to noncontrolling interest		(27,402)
Balance January 31, 2018	$	(31,720)

Table of Contents

Revenue Recognition

Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed pursuant to the terms of the arrangement, (iii) amounts are fixed or determinable, and (iv) the collectability of amounts is reasonably assured.

Patent Licensing Revenue

In certain instances, our past revenue arrangements have provided for the payment of contractually determined fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we had no further obligations. As such, the earnings process was complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met.

Intangible Assets

Our only identifiable intangible assets are patents and patent rights. We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life. We did not capitalize any patent acquisition costs during the three months ended January 31, 2018 and 2017. We recorded patent amortization expense of approximately $81,000 during each of the three-month periods ended January 31, 2018 and 2017, respectively.

2. STOCK BASED COMPENSATION

The Company maintains stock equity incentive plans under which the Company grants non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants.

Stock Option Compensation Expense

The compensation cost for service based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to ten years. We recorded stock-based compensation expense related to stock options granted to employees and directors of approximately $214,000 and $260,000 during the three months ended January 31, 2018 and 2017, respectively.

Table of Contents

For service based stock options granted to consultants we estimate the fair value of the stock options and recognize expense at each reporting period using the Black-Scholes pricing model. We recorded stock-based compensation expense related to stock options granted to consultants of approximately $53,000 and $-0- during the three months ended January 31, 2018 and 2017, respectively.

Stock Option Activity

During the three months ended January 31, 2018 and 2017, we granted options to purchase 50,000 shares and 106,000 shares of common stock, respectively, to employees, directors and consultants at weighted average exercise prices of $2.30 and $5.00 per share, respectively, pursuant to the ITUS Corporation 2010 Share Incentive Plan (the "2010 Share Plan”). During the three months ended January 31, 2018 and 2017, stock options to purchase 28,600 and 2,200 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $-0- and $6,000, respectively. Under certain circumstances, stock options may be exercised on a cashless basis. During the three months ended January 31, 2018 and 2017, 5,515 and -0- shares of common stock, respectively, were withheld in connection with cashless exercises of stock options.

Stock Option Plans

As of January 31, 2018, we have two stock option plans: the ITUS Corporation 2003 Share Incentive Plan (the "2003 Share Plan") and the 2010 Share Plan, which were adopted by our Board of Directors on April 21, 2003 and July 14, 2010, respectively.

The 2003 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future options on April 21, 2013. Information regarding the 2003 Share Plan for the three months ended January 31, 2018 is as follows:

		Weighted Average Exercise Price Per Share
				Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	30,600	$	3.16
Exercised	(10,600)	$	0.67
Forfeited	(5,600)	$	3.63
Options Outstanding and exercisable at January 31, 2018	14,400	$	4.81	$	17,280

The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of January 31, 2018:

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$ 0.67 - $17.50	14,400	1.31	$	4.81

Table of Contents

The 2010 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of January 31, 2018, the 2010 Share Plan had 802,450 shares available for future grants. Information regarding the 2010 Share Plan for the three months ended January 31, 2018 is as follows:

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	1,637,246	$	1.50
Granted	50,000	$	2.30
Exercised	(18,000)	$	0.67
Forfeited	(4,800)	$	3.80
Options Outstanding at January 31, 2018	1,664,446	$	1.52	$	3,752,696
Options Exercisable at January 31, 2018	1,013,106	$	1.72	$	2,120,876

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2018:

	Options Outstanding				Options Exercisable
		Weighted Average Remaining Contractual Life (in years)				Weighted Average Remaining Contractual Life (in years)
								Weighted Average Exercise Price
				Weighted Average Exercise Price
Range of Exercise Prices	Number Outstanding				Number Exercisable
Range of Exercise Prices	Number Outstanding				Number Exercisable

$0.67	983,000	7.40	$	0.67	556,754	6.18	$	0.67
$ 2.27 - $ 7.00	681,446	6.00	$	2.75	456,352	4.61	$	2.99

In addition to options granted under the 2003 Share Plan and the 2010 Share Plan, the Board of Directors approved the grant of stock options to purchase 1,780,000 shares. Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan for the three months ended January 31, 2018 is as follows:

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	1,780,000	$	1.58
Options Outstanding and exercisable at January 31, 2018	1,780,000	$	1.58	$	3,953,820

The following table summarizes information about stock options outstanding and exercisable that were not granted under the 2003 Share Plan or the 2010 Share Plan as of January 31, 2018:

Table of Contents

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$0.67	1,046,000	4.66	$	0.67
$ 2.58-$ 5.56	734,000	4.11	$	2.88

Stock Awards

We account for stock awards granted to employees, directors and consultants based on the grant date market price of the underlying common stock. During the three months ended January 31, 2018 and 2017, we issued 5,347 shares and 3,463 shares, respectively, of common stock to consultants for services rendered. We recorded consulting expense for the three months ended January 31, 2018 and 2017 of approximately $15,000 and $18,000, respectively, for the shares of common stock issued to consultants.

3. FAIR VALUE MEASUREMENTS

US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date.

Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities.

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2018:

Table of Contents

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	2,470,624	$	-	$	-	$	2,470,624
Certificates of deposit – Short-term investments		-		2,650,000		-		2,650,000
Total financial assets	$	2,470,624	$	2,650,000	$	-	$	5,120,624

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2017:

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	3,079,282	$	-	$	-	$	3,079,282
Certificates of deposit – Short term investments		-		3,500,000		-		3,500,000
Total financial assets	$	3,079,282	$	3,500,000	$	-	$	6,579,232

Our non-financial assets that are measured on a non-recurring basis include our patents and property and equipment which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.

4. SHORT-TERM INVESTMENTS

At January 31, 2018 and October 31, 2017, we had certificates of deposit of $2,650,000 and $3,500,000, respectively, which were classified as short-term investments and reported at fair value.

5. ACCRUED EXPENSES

Accrued expense consist of the following as of:

	January 31, 2018		October 31, 2017
	January 31, 2018		October 31, 2017
Accrued severance costs		161,475		237,563
Payroll and related expenses		178,916		51,643
Accrued collaborative research and license expenses		220,431		-
Accrued other		108,811		119,963
	$	669,633	$	409,169

Table of Contents

6. PREFERRED STOCK REDEMPTION

On November 11, 2016, the holder of all our outstanding Series A Preferred Stock (the “Series A Preferred”) with an aggregate stated value of $3,500,000 exercised its right of redemption to receive such amount from proceeds from the sale of the Company’s equity securities. On December 6, 2016, we entered into an agreement with the holder of the Series A Preferred setting forth the terms under which such redemption would take place (the “Series A Redemption Terms”). Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which was due on or before June 1, 2017 and the remainder of which was due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”). The Redemption Debenture was secured by a lien on the Company’s assets and prohibited the Company from incurring any senior indebtedness other than equipment financing in connection with the Company’s business. The Redemption Debenture was paid in full during fiscal year 2017.

The difference between the fair value of the consideration given to the holder of our Series A Preferred and the carrying value of the Series A Preferred represents a return to the preferred shareholder which is treated in a similar manner as that of dividends paid on preferred stock. In the redemption, the Series A Preferred holder received $500,000 in cash, the Redemption Debenture with a present value of approximately $2,999,000 and the Redemption Warrant with a fair value of approximately $2,801,000, determined using the Black Scholes pricing model, and waived the Series A Preferred’s conversion right with an intrinsic value of approximately $792,000, resulting in total consideration given to the Series A Preferred holder of approximately $5,508,000. The difference between the fair value of the consideration and the $3,500,000 carrying value of the Series A Preferred resulted in a deemed dividend to the Series A Preferred holder of approximately $2,008,000.

7. NET INCOME (LOSS) PER SHARE OF COMMON STOCK

Basic net income (loss) per common share (“Basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted net income (loss) per common share (“Diluted EPS”) is computed by dividing net income (loss) by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. The treasury stock method reduces the dilutive effect of potentially dilutive securities as it assumes that any cash proceeds (from the issuance of potentially dilutive securities) are used to buy back shares at the average share price during the period.

Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the three months ended January 31, 2018 and 2017, were stock options to purchase 3,458,846 and 3,162,272 shares, respectively, and warrants to purchase 829,400 and 837,405 shares, respectively.

Table of Contents

8. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers. This amendment updates addressing revenue from contracts with customers, which clarifies existing accounting literature relating to how and when a company recognizes revenue. Under the standard, a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. This standard update is effective for interim and annual reporting periods beginning after December 15, 2016, and were to be applied retrospectively or the cumulative effect as of the date of adoption, with early application not permitted. In July 2015, a one-year deferral of the effective date of the new guidance was approved. We do not expect the adoption of ASU 2014-09 to have a material impact on our consolidated financial statements and related disclosures.

In November 2015, the FASB issued Accounting Standards Update 2015-17 (“ASU 2015-17”) to simplify the presentation of deferred taxes. This amendment requires that all deferred tax assets and liabilities, along with any related valuation allowances, be classified as noncurrent on the balance sheet. Adoption of this standard is required for annual periods beginning after December 15, 2016. The adoption of this amendment did not have an impact on our consolidated financial statements and related disclosures as we currently do not present deferred tax assets or liabilities.

In February 2016, the FASB issued Accounting Standards Update 2016-02 (“ASU 2016-02”) which requires lessees to recognize most leases on the balance sheet. This is expected to increase both reported assets and liabilities. The new lease standard does not substantially change lessor accounting. For public companies, the standard will be effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption is permitted. Lessees and lessors will be required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance, using a modified retrospective transition method. The requirements of this standard include a significant increase in required disclosures. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is currently ongoing.

In March 2016, the FASB issued Accounting Standards Update 2016-09 (“ASU 2016-09”) that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election for forfeitures as they occur. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-09 on November 1, 2017 and the adoption did not have an impact on our consolidated financial statements and related disclosures.

Table of Contents

In May 2017, the FASB issued Accounting Standards Update 2017-09 (“ASU 2017-09”) that provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting. This update is effective for all entities for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing.

9. INCOME TAXES

We file Federal, New York, California and Pennsylvania state income tax returns. Due to net operating losses, the statute of limitations for Federal and New York State income tax returns remains open to examination by taxing authorities since the fiscal year ended October 31, 1998. We account for interest and penalties related to income tax matters, if any, in general and administrative expenses. There are no unrecognized income tax benefits as of January 31, 2018 and October 31, 2017.

We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have substantial net operating loss carryforwards for Federal, New York State and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets.

10. COMMITMENT AND CONTINGENCES

Litigation Matters

Other than suits we bring to enforce our patent rights we are not a party to any material pending legal proceedings other than that which arise in the ordinary course of business. We believe that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on our financial position or results of operations.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

GENERAL

Table of Contents

RESULTS OF OPERATIONS

Three months ended January 31, 2018 compared with three months ended January 31, 2017

Revenue

We had no revenue during the three-month periods ended January 31, 2018 and 2017.

Inventor Royalties, Contingent Legal Fees and Litigation and Licensing Expenses Related to Patent Assertion

Inventor royalties, contingent legal fees and litigation and licensing expenses related to patent assertion activities were approximately $25,000 in the three months ended January 31, 2018 compared to approximately $2,000 in the comparable prior year period due to expenses related to continuing litigation. Inventor royalties and contingent legal fees are expensed in the period that the related revenues are recognized. Litigation and licensing expenses related to patent assertion, other than contingent legal fees, are expensed in the period incurred.

Amortization of Patents

Amortization of patents was approximately $81,000 in each of the three-month periods ended January 31, 2018 and 2017, respectively. We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life.

Table of Contents

Research and Development Expenses

Research and development expenses are related to the development of our early cancer detection and cancer immune-therapy drug platforms and increased by approximately $326,000 to approximately $778,000 in the three months ended January 31, 2018, from approximately $452,000 in the three months ended January 31, 2017. The increase in research and development expenses was primarily due to an increase in costs related to our collaboration and license agreements with Wistar and the initiation of our collaboration agreement with Moffitt of approximately $363,000 and an increase in employee compensation and related costs, other than stock option expense, of approximately $42,000, offset by a decrease in employee stock option expense of approximately $40,000 and a decrease in patent development costs of approximately $26,000.

General and Administrative Expenses

General and administrative expenses increased by approximately $130,000 to approximately $990,000 in the three months ended January 31, 2018, from approximately $860,000 in the three months ended January 31, 2017. The increase in general and administrative expenses was principally due to an increase in legal and accounting fees of approximately $120,000 due primarily to potential strategic transactions, the commencement and subsequent termination of an at-the-market equity program and the special shareholder meeting scheduled for March 2018, an increase in consultant stock option expense of approximately $53,000 and an increase in consultant fees of approximately $22,000, offset by a decrease in employee compensation of approximately $70,000.

Interest Expense

Interest expense decreased from approximately $195,000 in the three months ended January 31, 2017 to $-0- in the current period due to the payment in full of the patent acquisition obligation and the secured debenture during fiscal year 2017.

Interest Income

Interest income increased by approximately $8,000 to approximately $9,000 in the three months ended January 31, 2018, from approximately $1,000 in the comparable prior year period as a result of additional cash on hand.

Net Loss Attributable to Noncontrolling Interest

The net loss attributable to noncontrolling interest of approximately $27,000 in the three months ended January 31, 2018 represents Wistar’s 5% ownership interest in Certainty’s net loss for the three-month period.

Deemed Dividend to Preferred Shareholder

The deemed dividend to preferred shareholder of approximately $2,009,000 in 2017 resulted from the redemption of our Series A Preferred. The difference between the fair value of the consideration given to the holder of our Series A Preferred and the carrying value of the Series A Preferred represented a return to the preferred shareholder and was treated in a similar manner as that of dividends paid on preferred stock.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of liquidity are cash, cash equivalents and short-term investments.

Based on currently available information as of March 8, 2018, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next 12 months. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies that are synergistic with or complimentary to our technologies, we may be required to obtain more working capital. We may seek to obtain working capital during our fiscal year ending 2018 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding,the sale of additional equity securities or convertible debt could result in dilution to our shareholders. Additionally, the sale of equity securities or issuance of debt securities may be subject to certain security holder approvals or may result in the downward adjustment of the exercise or conversion price of our outstanding securities. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations.

CRITICAL ACCOUNTING POLICIES

The Company’s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America. In preparing these financial statements, we make assumptions, judgments and estimates that can have a significant impact on amounts reported in our condensed consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.

Table of Contents

We believe that, of the significant accounting policies discussed in Note 2 to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2017, the following accounting policies require our most difficult, subjective or complex judgments:

Revenue Recognition; and

Stock-Based Compensation

Revenue Recognition

Patent Licensing Revenue

Stock-Based Compensation

The compensation cost for service based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to ten years. For service based stock options granted to consultants we estimate the fair value of the stock options and recognize expense at each reporting period using the Black-Scholes pricing model.

Table of Contents

The Black-Scholes pricing model requires the input of highly subjective assumptions. These variables include, but are not limited to, our stock price volatility over the term of the stock options, and actual and projected employee stock option exercise behaviors.

EFFECT OF RECENTLY ISSUED PRONOUNCEMENTS

We discuss the effect of recently issued pronouncements in the Notes to our Condensed Consolidated Financial Statements.

FORWARD-LOOKING STATEMENTS

Information included in this Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended October 31, 2017 and the condensed consolidated financial statements included in this Report. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As of January 31, 2018, we had investments in short-term, fixed rate and highly liquid instruments that have historically been reinvested when they mature throughout the year. Although our existing instruments are not considered at risk with respect to changes in interest rates or markets for these instruments, our rate of return on these securities could be affected at the time of reinvestment, if any.

Item 4. Controls and Procedures.

We carried out an evaluation, under the supervision and with the participation of our management including our President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13-15(b) of the Securities Exchange Act of 1934, as amended. Based upon that evaluation, our President and Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report.

Table of Contents

There was no change in our internal control over financial reporting during the first quarter of fiscal year 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended October 31, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the three months ended January 31, 2018, the Company issued an aggregate of 5,347 shares of our common stock to a company in payment of investor relations services. The common stock was issued in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act as they were issued to recipients, without a view to distribution, and were not issued through any general solicitation or advertisement.

Item 3. Defaults Upon Senior Securities. None.

Item 4. Mine Safety Disclosures. Not Applicable.

Item 5. Other Information. None.

Item 6. Exhibits.

31.1 Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 8, 2018.

31.2 Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 8, 2018.

32.1 Statement of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 8, 2018.

32.2 Statement of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 8, 201.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ITUS CORPORATION

	By:	/s/ Dr. Amit Kumar
		Dr. Amit Kumar
		Chairman, President and Chief Executive Officer
March 8, 2018		(Principal Executive Officer)


	By:	/s/ Michael J. Catelani
		Michael J. Catelani
		Chief Operating Officer and Chief Financial Officer
		(Principal Financial and
March 8, 2018		Accounting Officer)

EX-31.1 2 exhibit31_1.htm EXHIBIT 31.1 Exhibit 31.1

Exhibit 31.1

CERTIFICATION

I, Dr. Amit Kumar, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ITUS Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Dr. Amit Kumar
	Dr. Amit Kumar
	Chairman, President and
	Chief Executive Officer
March 8, 2018	(Principal Executive Officer)

EX-31.2 3 exhibit31_2.htm EXHIBIT 31.2 Exhibit 31.2

Exhibit 31.2

CERTIFICATION

I, Michael J. Catelani, certify that:

1. I have reviewed this quarterly report on Form 10-Q of ITUS Corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Michael J. Catelani
	Michael J. Catelani
	Chief Operating Officer and
	Chief Financial Officer
	(Principal Financial and
March 8, 2018	Accounting Officer)

EX-32.2 4 exhibit32_1.htm EXHIBIT 32.1 Exhibit 32.1

Exhibit 32.1

Statement of Chief Executive Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Dr. Amit Kumar, the Chairman, President and Chief Executive Officer of ITUS Corporation, hereby certifies that:

The Company's Form 10-Q Quarterly Report for the period ended January 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Dr. Amit Kumar
	Dr. Amit Kumar
	Chairman, President and
	Chief Executive Officer
March 8, 2018	(Principal Executive Officer)

EX-32.2 5 exhibit32_2.htm EXHIBIT 32.2 Exhibit 32.2

Exhibit 32.2

Statement of Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned, Michael J. Catelani, the Chief Operating Officer and Chief Financial Officer of ITUS Corporation, hereby certifies that:

The Company's Form 10-Q Quarterly Report for the period ended January 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Michael J. Catelani
	Michael J. Catelani
	Chief Operating Officer and
	Chief Financial Officer
	(Principal Financial and
March 8, 2018	Accounting Officer)

EX-101.INS 6 itus-20180131.xml XBRL INSTANCE DOCUMENT 0000715446 2018-01-31 0000715446 2017-10-31 0000715446 us-gaap:PreferredStockMember 2018-01-31 0000715446 us-gaap:PreferredStockMember 2017-10-31 0000715446 us-gaap:SeriesAPreferredStockMember 2018-01-31 0000715446 us-gaap:SeriesAPreferredStockMember 2017-10-31 0000715446 2017-11-01 2018-01-31 0000715446 2016-11-01 2017-01-31 0000715446 us-gaap:ResearchAndDevelopmentExpenseMember 2017-11-01 2018-01-31 0000715446 us-gaap:ResearchAndDevelopmentExpenseMember 2016-11-01 2017-01-31 0000715446 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-11-01 2018-01-31 0000715446 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-11-01 2017-01-31 0000715446 us-gaap:CommonStockMember 2017-10-31 0000715446 us-gaap:AdditionalPaidInCapitalMember 2017-10-31 0000715446 us-gaap:RetainedEarningsMember 2017-10-31 0000715446 itus:TotalShareholdersEquityMember 2017-10-31 0000715446 us-gaap:AdditionalPaidInCapitalMember 2017-11-01 2018-01-31 0000715446 itus:TotalShareholdersEquityMember 2017-11-01 2018-01-31 0000715446 us-gaap:CommonStockMember 2017-11-01 2018-01-31 0000715446 us-gaap:NoncontrollingInterestMember 2017-11-01 2018-01-31 0000715446 us-gaap:RetainedEarningsMember 2017-11-01 2018-01-31 0000715446 us-gaap:CommonStockMember 2018-01-31 0000715446 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0000715446 us-gaap:RetainedEarningsMember 2018-01-31 0000715446 itus:TotalShareholdersEquityMember 2018-01-31 0000715446 us-gaap:NoncontrollingInterestMember 2018-01-31 0000715446 2016-10-31 0000715446 2017-01-31 0000715446 2018-03-05 0000715446 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2017-11-01 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2017-11-01 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember 2017-11-01 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember 2016-11-01 2017-01-31 0000715446 us-gaap:EmployeeStockOptionMember itus:ConsultantMember 2017-11-01 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember itus:ConsultantMember 2016-11-01 2017-01-31 0000715446 us-gaap:EmployeeStockOptionMember itus:A2010SharePlanMember 2017-11-01 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember itus:A2010SharePlanMember 2016-11-01 2017-01-31 0000715446 us-gaap:EmployeeStockOptionMember itus:A2010SharePlanMember 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2017-11-01 2018-01-31 0000715446 itus:A2003SharePlanMember 2017-11-01 2018-01-31 0000715446 itus:A2003SharePlanMember 2017-10-31 0000715446 itus:A2003SharePlanMember 2018-01-31 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices067To1750Member 2018-01-31 0000715446 itus:A2003SharePlanMember itus:RangeOfExercisePrices067To1750Member 2017-11-01 2018-01-31 0000715446 itus:A2010SharePlanMember 2017-11-01 2018-01-31 0000715446 itus:A2010SharePlanMember 2017-10-31 0000715446 itus:A2010SharePlanMember 2018-01-31 0000715446 itus:A2010SharePlanMember itus:RangeOfExercisePrices067Member 2018-01-31 0000715446 itus:A2010SharePlanMember itus:RangeOfExercisePrices067Member 2017-11-01 2018-01-31 0000715446 itus:A2010SharePlanMember itus:RangeOfExercisePrices227To700Member 2018-01-31 0000715446 itus:A2010SharePlanMember itus:RangeOfExercisePrices227To700Member 2017-11-01 2018-01-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2017-11-01 2018-01-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2017-10-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember 2018-01-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember itus:RangeOfExercisePrices067Member 2018-01-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember itus:RangeOfExercisePrices067Member 2017-11-01 2018-01-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember itus:RangeOfExercisePrices258To556Member 2018-01-31 0000715446 itus:StockOptionsNotGrantedUnder2003SharePlanOr2010SharePlanMember itus:RangeOfExercisePrices258To556Member 2017-11-01 2018-01-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2018-01-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2018-01-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2018-01-31 0000715446 us-gaap:CashEquivalentsMember 2018-01-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2018-01-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2018-01-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2018-01-31 0000715446 us-gaap:CertificatesOfDepositMember 2018-01-31 0000715446 us-gaap:FairValueInputsLevel1Member 2018-01-31 0000715446 us-gaap:FairValueInputsLevel2Member 2018-01-31 0000715446 us-gaap:FairValueInputsLevel3Member 2018-01-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2017-10-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2017-10-31 0000715446 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2017-10-31 0000715446 us-gaap:CashEquivalentsMember 2017-10-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2017-10-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2017-10-31 0000715446 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2017-10-31 0000715446 us-gaap:CertificatesOfDepositMember 2017-10-31 0000715446 us-gaap:FairValueInputsLevel1Member 2017-10-31 0000715446 us-gaap:FairValueInputsLevel2Member 2017-10-31 0000715446 us-gaap:FairValueInputsLevel3Member 2017-10-31 0000715446 2016-11-11 0000715446 2016-12-06 2016-12-06 0000715446 2016-12-09 2016-12-09 0000715446 us-gaap:SecuredDebtMember 2016-12-09 0000715446 itus:RedemptionDebentureMember 2016-12-09 0000715446 itus:DueOnOrBeforeJune12017Member 2016-12-09 0000715446 2016-12-09 0000715446 itus:RedemptionWarrantMember 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember 2017-11-01 2018-01-31 0000715446 us-gaap:EmployeeStockOptionMember 2016-11-01 2017-01-31 0000715446 us-gaap:WarrantMember 2017-11-01 2018-01-31 0000715446 us-gaap:WarrantMember 2016-11-01 2017-01-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

2846863

3339374

2650000

3500000

278496

174566

5775359

7013940

1664451 1745775

50828

52701

7490638

8812416

416925

480324

669633

409169

1086558

889493

166312

166028

164281744

163931079

-158012256

-156174184

6435800

7922923

-31720

6404080

7922923

7490638

8812416

1371660

1290336

39756

35725

100

19860

100

140

0.01

24000000

16631191

16602759

16631191

16602759

25353

2121

81324

777873

451630

990036

859885

1874586

1394960

-1874586

-1394960

195299

9112

999

-1865474

-1589260

-1865474

-1589260

-27402

-1838072

-1589260

2008775

-1838072

-3598035

-0.11

-0.41

16610770

8755057

40057

79700

226916

180037

16602759

166028

163931079

-156174184

7922923

214427

52546

23085

231

-231

5347

14949

15002

68974

-4318

64656

-1838072

-27402

16631191

166312

164281744

-158012256

6435800

-31720

214427

259737

52546

15002

17811

4391

10505

-141299

64656

103930

-93480

-63399

167453

260464

87738

-1339993

-729913

1250000

2100000

150000

2518

14121

847482

135879

500000

5665

-494335

-492511

-1088369

2488323

1399954

3000000

ITUS CORPORATION 10-Q --10-31 16631191 false 0000715446 Yes No Smaller Reporting Company No 2018 Q1 2018-01-31

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 1.         BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “ITUS” means ITUS Corporation and its wholly-owned subsidiaries.  From inception through October 2012, our primary operations involved the development of patented technologies in the areas of thin-film displays and encryption.  Commencing in October 2012 the primary operations of the Company involved the development, acquisition, licensing, and enforcement of patented technologies that were either owned or controlled by the Company. In June of 2015, the Company announced the formation of a new subsidiary, Anixa Diagnostics Corporation (“Anixa”), to develop a platform for non-invasive blood tests for the early detection of cancer.  That platform is called Cchek™.  In July of 2015, ITUS announced a collaborative research agreement with The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading National Cancer Institute designated cancer research center, for the purpose of validating our cancer detection methodologies and establishing protocols for identifying certain biomarkers in the blood which we identified and which are known to be associated with malignancies.  In August of 2016 and again in August of 2017, ITUS announced the renewal and expansion of our relationship with Wistar. From October of 2015 through January of 2017, ITUS announced that we had demonstrated the efficacy of our Cchek™ early cancer detection platform with 15 different types of cancer, including:  breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar and prostate.  Breast, lung, colon and prostate cancers represent the four largest categories of cancer worldwide. In November of 2017, the Company announced the formation of a new subsidiary, Certainty Therapeutics, Inc. (“Certainty”), to develop immuno-therapy drugs against cancer.  Certainty entered into a license agreement with Wistar pursuant to which Certainty was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Wistar relating to Wistar’s chimeric endocrine receptor targeted therapy technology (such technology being akin to chimeric antigen receptor T-cell (“CAR-T”) technology).  We plan to initially focus on the development of a treatment for ovarian cancer, but we also may pursue future applications of the technology for the development of treatments for additional solid tumors.  The license agreement requires Certainty to make certain cash and equity payments to Wistar.  With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common stock of Certainty.   On November 20, 2017, we announced that Certainty entered into a collaboration agreement with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”) to advance toward human clinical testing the CAR-T technology licensed by Certainty from Wistar aimed initially at treating ovarian cancer.  Certainty intends to work with researchers at Moffitt to complete studies necessary to submit an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). On January 29, 2018, we announced the results of a study augmenting data from our preliminary study released in December 2016. The majority of patient samples collected for this study were from breast cancer and prostate cancer patients, but several other types were also included. With the additional cancers included in this study, we have now demonstrated our technology with 20 types of cancer from solid tumors. In addition to the 15 cancer types noted above, we have evaluated bladder, cervical, head and neck, gastric and testicular cancers. Over the next several quarters, we expect Cchek™ and Certainty’s ovarian cancer treatment to be the primary focus of the Company.  As part of our legacy operations, the Company remains engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.  We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management. Over the past several quarters, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation.  In addition to Anixa and Certainty, the Company may make investments in and form new companies to develop additional emerging technologies. Funding and Management’s Plans During the three months ended January 31, 2018, cash used in operating activities was approximately $1,340,000.  Net cash provided by investing activities was approximately $847,000, which reflects the purchase of certificates of deposit totaling $1,250,000, offset by proceeds from the sale or maturity of certificates of deposit totaling $2,100,000 and the purchase of property and equipment of approximately $3,000.  As a result, our cash, cash equivalents and short-term investments at January 31, 2018 decreased by approximately $1,342,000 to approximately $5,497,000 from approximately $6,839,000 at the end of fiscal year 2017.  Based on currently available information as of March 8, 2018, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next 12 months.  However, our projections of future cash needs and cash flows may differ from actual results.  If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies that are synergistic with or complimentary to our technologies, we may be required to obtain more working capital.  We may seek to obtain working capital during our fiscal year ending 2018 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible.  We cannot be certain that additional funding will be available on acceptable terms, or at all.  If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our shareholders.  Additionally, the sale of equity securities or issuance of debt securities may be subject to certain security holder approvals or may result in the downward adjustment of the exercise or conversion price of our outstanding securities.  We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all.  If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition.  Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X.  Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed.  These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2017.  The accompanying October 31, 2017 consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (“US GAAP”).  The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of January 31, 2018, and results of operations and cash flows for the interim periods represented.  The results of operations for the three months ended January 31, 2018 are not necessarily indicative of the results to be expected for the entire year. Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity.  The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2018: <table style="width: 550.1pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 86%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Balance October 31, 2017 </td> <td style="height: 15pt; width: 2%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 12%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> 0 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 86%; white-space: nowrap; padding: 0in;" valign="bottom"> Issuance of noncontrolling interest in Certainty </td> <td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"> (4,318) </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 86%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Net loss attributable to noncontrolling interest </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #cceeff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #cceeff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> (27,402) </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 86%; white-space: nowrap; padding: 0in;" valign="bottom"> Balance January 31, 2018 </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> (31,720) </td> </tr> </table> Revenue Recognition Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed pursuant to the terms of the arrangement, (iii) amounts are fixed or determinable, and (iv) the collectability of amounts is reasonably assured. Patent Licensing Revenue In certain instances, our past revenue arrangements have provided for the payment of contractually determined fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company.  These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation.  In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents.  Pursuant to the terms of these agreements, we had no further obligations.   As such, the earnings process was complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met. Intangible Assets Our only identifiable intangible assets are patents and patent rights.  We capitalize patent and patent rights acquisition costs and amortize the cost over the estimated economic useful life.  We did not capitalize any patent acquisition costs during the three months ended January 31, 2018 and 2017.  We recorded patent amortization expense of approximately $81,000 during each of the three-month periods ended January 31, 2018 and 2017, respectively. </div>

1342000

5497000

6839000

<table style="width: 550.1pt; border-collapse: collapse; ; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 86%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Balance October 31, 2017 </td> <td style="height: 15pt; width: 2%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 12%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> 0 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 86%; white-space: nowrap; padding: 0in;" valign="bottom"> Issuance of noncontrolling interest in Certainty </td> <td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12%; white-space: nowrap; padding: 0in;" valign="bottom"> (4,318) </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 86%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom"> Net loss attributable to noncontrolling interest </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #cceeff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #cceeff; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> (27,402) </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 86%; white-space: nowrap; padding: 0in;" valign="bottom"> Balance January 31, 2018 </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> (31,720) </td> </tr> </table>

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 2.         STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for service based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is recognized as an expense on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to ten years.  We recorded stock-based compensation expense related to stock options granted to employees and directors of approximately $214,000 and $260,000 during the three months ended January 31, 2018 and 2017, respectively. For service based stock options granted to consultants we estimate the fair value of the stock options and recognize expense at each reporting period using the Black-Scholes pricing model.  We recorded stock-based compensation expense related to stock options granted to consultants of approximately $53,000 and $-0- during the three months ended January 31, 2018 and 2017, respectively. Stock Option Activity During the three months ended January 31, 2018 and 2017, we granted options to purchase 50,000 shares and 106,000 shares of common stock, respectively, to employees, directors and consultants at weighted average exercise prices of $2.30 and $5.00 per share, respectively, pursuant to the ITUS Corporation 2010 Share Incentive Plan (the "2010 Share Plan”).  During the three months ended January 31, 2018 and 2017, stock options to purchase 28,600 and 2,200 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $-0- and $6,000, respectively.  Under certain circumstances, stock options may be exercised on a cashless basis.  During the three months ended January 31, 2018 and 2017, 5,515 and -0- shares of common stock, respectively, were withheld in connection with cashless exercises of stock options. Stock Option Plans As of January 31, 2018, we have two stock option plans:  the ITUS Corporation 2003 Share Incentive Plan (the "2003 Share Plan") and the 2010 Share Plan, which were adopted by our Board of Directors on April 21, 2003 and July 14, 2010, respectively.  The 2003 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants.  In accordance with the provisions of the 2003 Share Plan, the plan terminated with respect to the ability to grant future options on April 21, 2013.  Information regarding the 2003 Share Plan for the three months ended January 31, 2018 is as follows: <table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:55.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:11.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:16.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="4" valign="bottom">  Weighted Average Exercise  Price Per Share</td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="HEIGHT:15pt; WIDTH:13.28%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:55.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:11.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:13.28%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom"> Aggregate Intrinsic Value</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:55.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:11.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:55.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:11.66%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Shares</td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:55.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding at October 31, 2017</td> <td style="HEIGHT:15pt; WIDTH:11.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> 30,600 </td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2.3%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:13.78%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 3.16 </td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:1.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:11.62%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:55.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Exercised</td> <td style="HEIGHT:15.75pt; WIDTH:11.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> (10,600)</td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2.3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:13.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 0.67 </td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:11.62%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:55.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Forfeited</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.66%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> (5,600)</td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2.3%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:13.78%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 3.63 </td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:11.62%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:55.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding and exercisable at     January 31, 2018</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:11.66%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; white-space: nowrap;" valign="bottom"> 14,400 </td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2.3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:13.78%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 4.81 </td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:1.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:11.62%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 17,280</td></tr></table> The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of January 31, 2018: <table style="width: 550.65pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="734" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 22.98%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Number Outstanding and Exercisable </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 22.98%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Remaining Contractual Life (in years) </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 23.06%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; white-space: nowrap; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 23.06%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise Price </td> </tr> <tr style="height: 15pt;"> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 22.98%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom">   $ 0.67 - $17.50 </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> 14,400 </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> 1.31 </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 23.06%; background: #cceeff; padding: 0in;" valign="bottom"> 4.81 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 23.06%; background: #cceeff; padding: 0in;" valign="bottom"> . </td> </tr> </table> The 2010 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants.  As of January 31, 2018, the 2010 Share Plan had 802,450 shares available for future grants.  Information regarding the 2010 Share Plan for the three months ended January 31, 2018 is as follows: <table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" rowspan="3" valign="bottom">  Weighted Average Exercise Price Per Share</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" rowspan="3" valign="bottom"> Aggregate Intrinsic Value</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Shares</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:56%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Options Outstanding at October 31, 2017</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> 1,637,246 </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.50 </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Granted</td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> 50,000 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2.30 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:56%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Exercised</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> (18,000)</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 0.67 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:16.5pt"> <td style="HEIGHT:16.5pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Forfeited</td> <td style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> (4,800)</td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3.80 </td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td style="HEIGHT:16.5pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"></td> </tr><tr style="HEIGHT:16.5pt"> <td style="HEIGHT:16.5pt; WIDTH:56%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Options Outstanding at January 31, 2018</td> <td style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> 1,664,446 </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.52 </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3,752,696 </td></tr> <tr style="HEIGHT:16.5pt"> <td style="HEIGHT:16.5pt; WIDTH:56%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Options Exercisable at January 31, 2018</td> <td style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:windowtext 2.25pt double; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:2.9pt; width: 12%; white-space: nowrap;" valign="bottom"> 1,013,106 </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:12%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.72 </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:12%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 2,120,876 </td></tr></table> The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2018: <table width="867" style="WIDTH:650pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:41.3%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:41.3%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Exercisable</td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life (in years)</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life  (in years)</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="4" valign="bottom"> Weighted Average Exercise  Price</td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom"> Weighted Average Exercise Price</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="2" valign="bottom"> Range of Exercise Prices</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="2" valign="bottom"> Number Outstanding</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="2" valign="bottom"> Number Exercisable</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $0.67 </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 983,000</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 7.40</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 0.67 </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 556,754</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 6.18</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 0.67 </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $ 2.27 - $ 7.00</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 681,446</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 6.00</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.75 </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 456,352</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 4.61</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.99 </td></tr></table> In addition to options granted under the 2003 Share Plan and the 2010 Share Plan, the Board of Directors approved the grant of stock options to purchase 1,780,000 shares.  Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan for the three months ended January 31, 2018 is as follows: <table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" rowspan="3" valign="bottom">  Weighted Average  Exercise Price Per Share</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 14%; white-space: nowrap;" rowspan="3" valign="bottom"> Aggregate Intrinsic Value</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Shares</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:56%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Options Outstanding at October 31, 2017</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:12%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,780,000</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.58 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15.75pt; WIDTH:12%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:16.5pt"> <td style="HEIGHT:16.5pt; WIDTH:56%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 56%; white-space: nowrap;" valign="bottom"> Options Outstanding and exercisable at     January 31, 2018</td> <td style="BORDER-TOP:0px; HEIGHT:16.5pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1,780,000</td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 1.58 </td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:16.5pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:16.5pt; WIDTH:12%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> 3,953,820 </td></tr></table> The following table summarizes information about stock options outstanding and exercisable that were not granted under the 2003 Share Plan or the 2010 Share Plan as of January 31, 2018: <table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:23%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:23%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 23%;" rowspan="4" valign="bottom"> Number Outstanding and Exercisable</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:23%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 23%;" rowspan="4" valign="bottom"> Weighted Average Remaining Contractual Life (in years)</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:23%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:23%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:23%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 23%;" rowspan="3" valign="bottom"> Weighted Average Exercise  Price</td></tr> <tr style="HEIGHT:15pt"> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:23%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 23%;" rowspan="2" valign="bottom"> Range of Exercise Prices</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> $0.67 </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> 1,046,000</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> 4.66</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> 0.67 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> $ 2.58-$ 5.56</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> 734,000</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> 4.11</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:23%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 23%;"> 2.88 </td></tr></table> Stock Awards We account for stock awards granted to employees, directors and consultants based on the grant date market price of the underlying common stock.  During the three months ended January 31, 2018 and 2017, we issued 5,347 shares and 3,463 shares, respectively, of common stock to consultants for services rendered.  We recorded consulting expense for the three months ended January 31, 2018 and 2017 of approximately $15,000 and $18,000, respectively, for the shares of common stock issued to consultants.  </div>

P1Y

P10Y

214000

260000

53000

50000

106000

2.30

5.00

28600

2200

6000

5515 0

802450

1780000

5347

3463

15000 18000

30600

3.16

10600

0.67

5600

3.63

14400 4.81 17280

<table style="width: 550.65pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="734" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 22.98%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Number Outstanding and Exercisable </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 22.98%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="4" valign="bottom"> Weighted Average Remaining Contractual Life (in years) </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 23.06%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; white-space: nowrap; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 23.06%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="3" valign="bottom"> Weighted Average Exercise Price </td> </tr> <tr style="height: 15pt;"> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 22.98%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" rowspan="2" valign="bottom"> Range of Exercise Prices </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom">   $ 0.67 - $17.50 </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> 14,400 </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> 1.31 </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> $ </td> <td style="height: 15pt; width: 23.06%; background: #cceeff; padding: 0in;" valign="bottom"> 4.81 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 22.98%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 2%; background: #cceeff; padding: 0in;" valign="bottom"> </td> <td style="height: 15pt; width: 23.06%; background: #cceeff; padding: 0in;" valign="bottom"> . </td> </tr> </table>

14400 P1Y113D 4.81

1637246

1.50

50000

2.30

18000

0.67

4800

3.80

1664446

1.52

3752696

1013106

1.72

2120876

<table width="867" style="WIDTH:650pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:41.3%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Outstanding</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td colspan="4" style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:41.3%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> Options Exercisable</td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life (in years)</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="5" valign="bottom"> Weighted Average Remaining Contractual  Life  (in years)</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="4" valign="bottom"> Weighted Average Exercise  Price</td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="3" valign="bottom"> Weighted Average Exercise Price</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="2" valign="bottom"> Range of Exercise Prices</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="2" valign="bottom"> Number Outstanding</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" rowspan="2" valign="bottom"> Number Exercisable</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $0.67 </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 983,000</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 7.40</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 0.67 </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 556,754</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 6.18</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 0.67 </td></tr> <tr style="HEIGHT:11.25pt"> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $ 2.27 - $ 7.00</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 681,446</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 6.00</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.75 </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:2.18%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:14.14%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 456,352</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 4.61</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:1.08%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:11.25pt; BORDER-RIGHT:0px; WIDTH:13.04%; BACKGROUND-IMAGE:none; BACKGROUND-REPEAT:repeat; BACKGROUND-ATTACHMENT:scroll; BORDER-BOTTOM:0px; BACKGROUND-POSITION:0% 0%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; white-space: nowrap;" valign="bottom"> 2.99 </td></tr></table>

983000

P7Y146D

0.67

556754

P6Y65D

0.67

681446

P6Y

2.75

456352

P4Y222D

2.99

1780000

1.58

1780000 1.58 3953820

1046000 P4Y240D 0.67 734000 P4Y40D 2.88

<table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> Money market funds –     Cash equivalents</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 2,470,624 </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%;" valign="bottom"> 2,470,624 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> Certificates of deposit –     Short-term investments</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 2,650,000 </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 2,650,000 </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:46%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> Total financial assets</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 2,470,624 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 2,650,000 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 5,120,624 </td></tr></table><table width="733" style="WIDTH:550pt; BACKGROUND:white; BORDER-COLLAPSE:collapse; margin-left: auto; margin-right: auto;" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom">  </td> <td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Level 1</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Level 2</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Level 3</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> </td><td colspan="2" style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:12%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 12%; white-space: nowrap;" valign="bottom"> Total</td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">       </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:10%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom">  </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> Money market funds –     Cash equivalents</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 3,079,282 </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="HEIGHT:15pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="HEIGHT:15pt; WIDTH:10%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 10%;" valign="bottom"> 3,079,282 </td></tr> <tr style="HEIGHT:15pt"> <td style="HEIGHT:15pt; WIDTH:46%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> Certificates of deposit –     Short term investments</td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 3,500,000 </td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15pt; WIDTH:2%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:2%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:10%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 3,500,000 </td></tr> <tr style="HEIGHT:15.75pt"> <td style="HEIGHT:15.75pt; WIDTH:46%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:10pt; PADDING-RIGHT:0in; width: 46%; white-space: nowrap;" valign="bottom"> Total financial assets</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 3,079,282 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 3,500,000 </td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> -</td> <td style="HEIGHT:15.75pt; WIDTH:2%; BACKGROUND:#cceeff; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom">  </td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:2%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 2%; white-space: nowrap;" valign="bottom"> $</td> <td style="BORDER-TOP:0px; HEIGHT:15.75pt; BORDER-RIGHT:0px; WIDTH:10%; BACKGROUND:#cceeff; BORDER-BOTTOM:windowtext 2.25pt double; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in; width: 10%; white-space: nowrap;" valign="bottom"> 6,579,232 </td></tr></table>

2470624

2650000

2470624

2650000

5120624

3079282

3500000

3079282

3500000

6579232

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 4.         SHORT-TERM INVESTMENTS At January 31, 2018 and October 31, 2017, we had certificates of deposit of $2,650,000 and $3,500,000, respectively, which were classified as short-term investments and reported at fair value.  </div>

2650000

3500000

<table style="width: 550pt; background: white; border-collapse: collapse; margin-left: auto; margin-right: auto;" width="733" cellspacing="0" cellpadding="0"> <tr style="height: 15pt;"> <td style="height: 15pt; width: 70.04%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 14.02%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" colspan="2" rowspan="2" valign="bottom"> January 31, 2018 </td> <td style="height: 15pt; width: 1.94%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 14%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" colspan="2" rowspan="2" valign="bottom"> October 31, 2017 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 70.04%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 1.94%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 70.04%; background: #cceeff; padding: 0in;" valign="bottom"> Accrued severance costs </td> <td style="height: 15pt; width: 2%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12.02%; background: #cceeff; padding: 0in;" valign="bottom"> 161,475 </td> <td style="height: 15pt; width: 1.94%; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12%; background: #cceeff; padding: 0in;" valign="bottom"> 237,563 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 70.04%; padding: 0in;" valign="bottom"> Payroll and related expenses </td> <td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12.02%; padding: 0in;" valign="bottom"> 178,916 </td> <td style="height: 15pt; width: 1.94%; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12%; padding: 0in;" valign="bottom"> 51,643 </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 70.04%; background: #cceeff; padding: 0in;" valign="bottom"> Accrued collaborative research and license expenses </td> <td style="height: 15pt; width: 2%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12.02%; background: #cceeff; padding: 0in;" valign="bottom"> 220,431 </td> <td style="height: 15pt; width: 1.94%; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 2%; background: #cceeff; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="height: 15pt; width: 12%; background: #cceeff; padding: 0in;" valign="bottom"> - </td> </tr> <tr style="height: 15pt;"> <td style="height: 15pt; width: 70.04%; padding: 0in;" valign="bottom"> Accrued other </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12.02%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom"> 108,811 </td> <td style="height: 15pt; width: 1.94%; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 2%; border-bottom: windowtext 1pt solid; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15pt; border-right: 0px; width: 12%; border-bottom: windowtext 1pt solid; border-left: 0px; padding: 0in;" valign="bottom"> 119,963 </td> </tr> <tr style="height: 15.75pt;"> <td style="height: 15.75pt; width: 70.04%; background: #cceeff; padding: 0in;" valign="bottom">  Total </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #cceeff; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12.02%; background: #cceeff; border-bottom: windowtext 2.25pt double; border-left: 0px; padding: 0in;" valign="bottom"> 669,633 </td> <td style="height: 15.75pt; width: 1.94%; background: #cceeff; padding: 0in;" valign="bottom">   </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 2%; background: #cceeff; border-bottom: windowtext 2.25pt double; border-left: 0px; white-space: nowrap; padding: 0in;" valign="bottom"> $ </td> <td style="border-top: 0px; height: 15.75pt; border-right: 0px; width: 12%; background: #cceeff; border-bottom: windowtext 2.25pt double; border-left: 0px; padding: 0in;" valign="bottom"> 409,169 </td> </tr> </table>

161475 237563

178916

51643

220431

108811

119963

3500000

Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which was due on or before June 1, 2017 and the remainder of which was due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”).

500000

0.12

3000000

1000000

P5Y

500000

0.10 2999000

2801000

792000 5508000

2008000

3458846

3162272

829400

837405

<div style="font-family: "Times New Roman","serif"; font-size: 12pt; "> 9.         INCOME TAXES We file Federal, New York, California and Pennsylvania state income tax returns.  Due to net operating losses, the statute of limitations for Federal and New York State income tax returns remains open to examination by taxing authorities since the fiscal year ended October 31, 1998.  We account for interest and penalties related to income tax matters, if any, in general and administrative expenses. There are no unrecognized income tax benefits as of January 31, 2018 and October 31, 2017. We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse.  A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have substantial net operating loss carryforwards for Federal, New York State and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. </div>

<div style="font-family: "Times New Roman"; font-size: 10pt; "> 10.       COMMITMENT AND CONTINGENCES  Litigation Matters Other than suits we bring to enforce our patent rights we are not a party to any material pending legal proceedings other than that which arise in the ordinary course of business.  We believe that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on our financial position or results of operations. </div>

EX-101.SCH 7 itus-20180131.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - BUSINESS AND FUNDING link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - SHORT-TERM INVESTMENTS link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - PREFERRED STOCK REDEMPTION link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - COMMITMENT AND CONTINGENCES link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - BUSINESS AND FUNDING (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - BUSINESS AND FUNDING (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - BUSINESS AND FUNDING (Details) - Changes in noncontrolling interest link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - STOCK BASED COMPENSATION (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2003 Share Plan link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2010 Share Plan link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable not granted under the 2003 Share Plan or the 2010 Share Plan link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - SHORT-TERM INVESTMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - ACCRUED EXPENSES (Details) - Accrued liabilities link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - PREFERRED STOCK REDEMPTION (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 itus-20180131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 itus-20180131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 itus-20180131_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Statement of Financial Position [Abstract] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Short-term investments in certificates of deposit Prepaid expenses and other current assets Total current assets Patents, net of accumulated amortization of $1,371,660 and $1,290,336, respectively Patents, accumulated amortization (in Dollars) Property and equipment, net of accumulated depreciation of $39,756 and $35,725, respectively Property and equipment, accumulated depreciation (in Dollars) Total assets Accounts payable Accrued expenses Total Total current liabilities Commitments and contingencies (Note 10) Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding Equity Interest Type [Axis] Preferred Stock [Member] Preferred stock par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Class of Stock [Axis] Series A Preferred Stock [Member] Common stock, par value $.01 per share; 24,000,000 shares authorized; 16,631,191 and 16,602,759 shares issued and outstanding, respectively Common stock par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Total shareholders’ equity Noncontrolling interest (Note 1) Balance October 31, 2017 Balance January 31, 2018 Total equity Balance, October 31, 2017 Balance, January 31, 2018 Total liabilities and equity Income Statement [Abstract] Revenue Inventor royalties, contingent legal fees and litigation and licensing expenses related to patent assertion Amortization of patents Amortization of Intangible Assets Research and development expenses (including non-cash stock option compensation expense of $40,057 and $79,700, respectively) Income Statement Location [Axis] Research and Development Expense [Member] Non-cash Stock option compensation expenses General and administrative expenses (including non-cash stock option compensation expense of $226,916 and $180,037 respectively) Selling, General and Administrative Expenses [Member] Total operating costs and expenses Loss from operations Interest expense Interest income Loss before income taxes Provision for income taxes Net loss Net loss Less: Net loss attributable to noncontrolling interest Net loss attributable to noncontrolling interest Net loss attributable to common shareholders before deemed dividend Deemed dividend to preferred shareholder (Note 6) Net loss attributable to common shareholders Basic and diluted (in Dollars per share) Basic and diluted (in Shares) Statement of Stockholders' Equity [Abstract] Balance, October 31, 2017 (in Shares) Balance, January 31, 2018 (in Shares) Stock option compensation to employees and directors Stock option compensation to consultants Common stock issued upon exercise of stock options Common stock issued upon exercise of stock options (in Shares) Exercised Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Common stock issued to consultants Common stock issued to consultants (in Shares) Stock Issued During Period, Shares, Issued for Services Issuance of noncontrolling interest in Certainty Therapeutics, Inc Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Shareholders' Equity [Member] Noncontrolling Interest [Member] Statement of Cash Flows [Abstract] Stock option compensation to employees and directors Stock option compensation to consultants Common stock issued to consultants Depreciation of property and equipment Accretion of interest on patent acquisition obligations to interest expense Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee Issuance of noncontrolling interest in Certainty Prepaid expenses and other current assets Accounts payable Accrued expenses Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Disbursements to acquire short-term investments in certificates of deposit Payments to Acquire Short-term Investments Proceeds from maturities of short-term investments in certificates of deposit Proceeds from Sale of Short-term Investments Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Redemption of convertible preferred stock Proceeds from exercise of employee stock options Proceeds from Stock Options Exercised (in Dollars) Net cash used in by financing activities Net decrease in cash and cash equivalents Redemption of Series A convertible preferred stock into secured debenture (Note 6) Accounting Policies [Abstract] Changes in noncontrolling interest [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Plan Name [Axis] 2003 Share Plan [Member] Information regarding the 2003 Share Plan [Abstract] Options Outstanding at October 31, 2017 Options Outstanding at January 31, 2018 Options Outstanding at October 31, 2017 Options Outstanding at October 31, 2017 Options Outstanding at January 31, 2018 Options Outstanding at October 31, 2017 Exercised Forfeited Forfeited Forfeited Options Outstanding and exercisable at January 31, 2018 Options Outstanding and exercisable at January 31, 2018 Options Outstanding and exercisable at January 31, 2018 Options Outstanding and exercisable at January 31, 2018 Options Outstanding and exercisable at January 31, 2018 Options Outstanding and exercisable at January 31, 2018 Stock options outstanding and exercisable under the 2003 Share Plan [Abstract] Exercise Price Range [Axis] Range Of Exercise Prices $0.67 To $17.50 [Member] Options Outstanding and Exercisable, Number Options Outstanding and Exercisable, Number Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life Options Outstanding and Exercisable, Weighted Average Exercise Price Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) 2010 Share Plan [Member] Information regarding the 2010 Share Plan [Abstract] Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) Options Outstanding at January 31, 2018 Options Exercisable at January 31, 2018 Options Exercisable at January 31, 2018 Options Exercisable at January 31, 2018 Stock options outstanding and exercisable under the 2010 Share Plan [Abstract] Range Of Exercise Prices $0.67 [Member] Options Outstanding, Number Options Outstanding,Weighted Average Remaining Contractual Life Options Outstanding, Weighted Average Exercise Price (in Dollars per share) Options Exercisable, Number Options Exercisable,Weighted Average Remaining Contractual Life Options Exercisable, Weighted Average Exercise Price (in Dollars per share) Range Of Exercise Prices $2.27 To $7.00 [Member] Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan [Abstract] Stock options outstanding and exercisable not granted under the 2003 Share Plan or the 2010 Share Plan [Abstract] Range Of Exercise Prices $2.58 To $5.56 [Member] Fair Value Disclosures [Abstract] Hierarchy for financial assets measured at fair value [Abstract] Asset Class [Axis] Cash Equivalents [Member] Financial assets Certificates of Deposit [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Investments Schedule [Abstract] Payables and Accruals [Abstract] Accrued liabilities [Abstract] Accrued severance costs Payroll and related expenses Accrued collaborative research and license expenses Accrued other Disclosure Text Block Supplement [Abstract] Earnings Per Share [Abstract] Net loss per share attributable to common shareholders: New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Income Tax Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Current assets: LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Equity: Shareholders’ equity: The accompanying notes are an integral part of these condensed consolidated financial statements. Operating costs and expenses: Weighted average common shares outstanding: The accompanying notes are an integral part of these condensed consolidated financial statements. The accompanying notes are an integral part of these condensed consolidated financial statements. Reconciliation of net loss to net cash used in operating activities: Change in operating assets and liabilities: Cash flows from investing activities: Cash flows from financing activities: Supplemental disclosure of non-cash financing activities: The accompanying notes are an integral part of these statements. Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Schedule of Variable Interest Entities [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] EX-101.PRE 11 itus-20180131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Jan. 31, 2018	Mar. 05, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ITUS CORPORATION
Document Type	10-Q
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		16,631,191
Amendment Flag	false
Entity Central Index Key	0000715446
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jan. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Current assets:
Cash and cash equivalents	$ 2,846,863	$ 3,339,374
Short-term investments in certificates of deposit	2,650,000	3,500,000
Prepaid expenses and other current assets	278,496	174,566
Total current assets	5,775,359	7,013,940
Patents, net of accumulated amortization of $1,371,660 and $1,290,336, respectively	1,664,451	1,745,775
Property and equipment, net of accumulated depreciation of $39,756 and $35,725, respectively	50,828	52,701
Total assets	7,490,638	8,812,416
Current liabilities:
Accounts payable	416,925	480,324
Accrued expenses	669,633	409,169
Total current liabilities	1,086,558	889,493
Commitments and contingencies (Note 10)
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Common stock, par value $.01 per share; 24,000,000 shares authorized; 16,631,191 and 16,602,759 shares issued and outstanding, respectively	166,312	166,028
Additional paid-in capital	164,281,744	163,931,079
Accumulated deficit	(158,012,256)	(156,174,184)
Total shareholders’ equity	6,435,800	7,922,923
Noncontrolling interest (Note 1)	(31,720)	0
Total equity	6,404,080	7,922,923
Total liabilities and equity	7,490,638	8,812,416
Series A Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding and Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Patents, accumulated amortization (in Dollars)	$ 1,371,660	$ 1,290,336
Property and equipment, accumulated depreciation (in Dollars)	$ 39,756	$ 35,725
Common stock par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	24,000,000	24,000,000
Common stock, shares issued	16,631,191	16,602,759
Common stock, shares outstanding	16,631,191	16,602,759
Series A Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred Stock [Member]
Preferred stock par value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Revenue
Operating costs and expenses:
Inventor royalties, contingent legal fees and litigation and licensing expenses related to patent assertion	25,353	2,121
Amortization of patents	81,324	81,324
Research and development expenses (including non-cash stock option compensation expense of $40,057 and $79,700, respectively)	777,873	451,630
General and administrative expenses (including non-cash stock option compensation expense of $226,916 and $180,037 respectively)	990,036	859,885
Total operating costs and expenses	1,874,586	1,394,960
Loss from operations	(1,874,586)	(1,394,960)
Interest expense		(195,299)
Interest income	9,112	999
Loss before income taxes	(1,865,474)	(1,589,260)
Provision for income taxes
Net loss	(1,865,474)	(1,589,260)
Less: Net loss attributable to noncontrolling interest	(27,402)
Net loss attributable to common shareholders before deemed dividend	(1,838,072)	(1,589,260)
Deemed dividend to preferred shareholder (Note 6)		(2,008,775)
Net loss attributable to common shareholders	$ (1,838,072)	$ (3,598,035)
Net loss per share attributable to common shareholders:
Basic and diluted (in Dollars per share)	$ (0.11)	$ (0.41)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	16,610,770	8,755,057

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Research and Development Expense [Member]
Non-cash Stock option compensation expenses	$ 40,057	$ 79,700
Selling, General and Administrative Expenses [Member]
Non-cash Stock option compensation expenses	$ 226,916	$ 180,037

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) - 3 months ended Jan. 31, 2018 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total Shareholders' Equity [Member]	Noncontrolling Interest [Member]	Total
Balance, October 31, 2017 at Oct. 31, 2017	$ 166,028	$ 163,931,079	$ (156,174,184)	$ 7,922,923		$ 7,922,923
Balance, October 31, 2017 (in Shares) at Oct. 31, 2017	16,602,759
Stock option compensation to employees and directors		214,427		214,427		214,427
Stock option compensation to consultants		52,546		52,546		52,546
Common stock issued upon exercise of stock options	$ 231	(231)
Common stock issued upon exercise of stock options (in Shares)	23,085
Common stock issued to consultants	$ 53	14,949		15,002		15,002
Common stock issued to consultants (in Shares)	5,347
Issuance of noncontrolling interest in Certainty Therapeutics, Inc		68,974		68,974	$ (4,318)	64,656
Net loss			(1,838,072)	(1,838,072)	(27,402)	(1,865,474)
Balance, January 31, 2018 at Jan. 31, 2018	$ 166,312	$ 164,281,744	$ (158,012,256)	$ 6,435,800	$ (31,720)	$ 6,404,080
Balance, January 31, 2018 (in Shares) at Jan. 31, 2018	16,631,191

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (1,865,474)	$ (1,589,260)
Stock option compensation to employees and directors	214,427	259,737
Stock option compensation to consultants	52,546
Common stock issued to consultants	15,002	17,811
Depreciation of property and equipment	4,391	10,505
Amortization of patents	81,324	81,324
Accretion of interest on patent acquisition obligations to interest expense		141,299
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee	64,656
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(103,930)	93,480
Accounts payable	(63,399)	167,453
Accrued expenses	260,464	87,738
Net cash used in operating activities	(1,339,993)	(729,913)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(1,250,000)
Proceeds from maturities of short-term investments in certificates of deposit	2,100,000	150,000
Purchase of property and equipment	(2,518)	(14,121)
Net cash provided by investing activities	847,482	135,879
Cash flows from financing activities:
Redemption of convertible preferred stock		(500,000)
Proceeds from exercise of employee stock options		5,665
Net cash used in by financing activities		(494,335)
Net decrease in cash and cash equivalents	(492,511)	(1,088,369)
Cash and cash equivalents at beginning of period	3,339,374	2,488,323
Cash and cash equivalents at end of period	2,846,863	1,399,954
Supplemental disclosure of non-cash financing activities:
Redemption of Series A convertible preferred stock into secured debenture (Note 6)		$ (3,000,000)

XML 19 R8.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING

3 Months Ended

Jan. 31, 2018

Accounting Policies [Abstract]

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

1. BUSINESS AND FUNDING

Description of Business

In June of 2015, the Company announced the formation of a new subsidiary, Anixa Diagnostics Corporation (“Anixa”), to develop a platform for non-invasive blood tests for the early detection of cancer. That platform is called Cchek™. In July of 2015, ITUS announced a collaborative research agreement with The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading National Cancer Institute designated cancer research center, for the purpose of validating our cancer detection methodologies and establishing protocols for identifying certain biomarkers in the blood which we identified and which are known to be associated with malignancies. In August of 2016 and again in August of 2017, ITUS announced the renewal and expansion of our relationship with Wistar.

From October of 2015 through January of 2017, ITUS announced that we had demonstrated the efficacy of our Cchek™ early cancer detection platform with 15 different types of cancer, including: breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar and prostate. Breast, lung, colon and prostate cancers represent the four largest categories of cancer worldwide.

Funding and Management’s Plans

Basis of Presentation

Noncontrolling Interest

Balance October 31, 2017	$	0
Issuance of noncontrolling interest in Certainty		(4,318)
Net loss attributable to noncontrolling interest		(27,402)
Balance January 31, 2018	$	(31,720)

Revenue Recognition

Patent Licensing Revenue

Intangible Assets

XML 20 R9.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION

3 Months Ended

Jan. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

2. STOCK BASED COMPENSATION

Stock Option Compensation Expense

Stock Option Activity

Stock Option Plans

		Weighted Average Exercise Price Per Share
				Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	30,600	$	3.16
Exercised	(10,600)	$	0.67
Forfeited	(5,600)	$	3.63
Options Outstanding and exercisable at January 31, 2018	14,400	$	4.81	$	17,280

The following table summarizes information about stock options outstanding and exercisable under the 2003 Share Plan as of January 31, 2018:

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$ 0.67 - $17.50	14,400	1.31	$	4.81
				.

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	1,637,246	$	1.50
Granted	50,000	$	2.30
Exercised	(18,000)	$	0.67
Forfeited	(4,800)	$	3.80
Options Outstanding at January 31, 2018	1,664,446	$	1.52	$	3,752,696
Options Exercisable at January 31, 2018	1,013,106	$	1.72	$	2,120,876

The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2018:

	Options Outstanding				Options Exercisable
		Weighted Average Remaining Contractual Life (in years)				Weighted Average Remaining Contractual Life (in years)
								Weighted Average Exercise Price
				Weighted Average Exercise Price
Range of Exercise Prices	Number Outstanding				Number Exercisable
Range of Exercise Prices	Number Outstanding				Number Exercisable

$0.67	983,000	7.40	$	0.67	556,754	6.18	$	0.67
$ 2.27 - $ 7.00	681,446	6.00	$	2.75	456,352	4.61	$	2.99

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	1,780,000	$	1.58
Options Outstanding and exercisable at January 31, 2018	1,780,000	$	1.58	$	3,953,820

The following table summarizes information about stock options outstanding and exercisable that were not granted under the 2003 Share Plan or the 2010 Share Plan as of January 31, 2018:

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$0.67	1,046,000	4.66	$	0.67
$ 2.58-$ 5.56	734,000	4.11	$	2.88

Stock Awards

XML 21 R10.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

3 Months Ended

Jan. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

3. FAIR VALUE MEASUREMENTS

Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2018:

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	2,470,624	$	-	$	-	$	2,470,624
Certificates of deposit – Short-term investments		-		2,650,000		-		2,650,000
Total financial assets	$	2,470,624	$	2,650,000	$	-	$	5,120,624

The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2017:

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	3,079,282	$	-	$	-	$	3,079,282
Certificates of deposit – Short term investments		-		3,500,000		-		3,500,000
Total financial assets	$	3,079,282	$	3,500,000	$	-	$	6,579,232

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

SHORT-TERM INVESTMENTS	3 Months Ended
SHORT-TERM INVESTMENTS	Jan. 31, 2018
Investments Schedule [Abstract]
Investment [Text Block]	4. SHORT-TERM INVESTMENTS At January 31, 2018 and October 31, 2017, we had certificates of deposit of $2,650,000 and $3,500,000, respectively, which were classified as short-term investments and reported at fair value.

XML 23 R12.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES

3 Months Ended

Jan. 31, 2018

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5. ACCRUED EXPENSES

Accrued expense consist of the following as of:

	January 31, 2018		October 31, 2017
	January 31, 2018		October 31, 2017
Accrued severance costs		161,475		237,563
Payroll and related expenses		178,916		51,643
Accrued collaborative research and license expenses		220,431		-
Accrued other		108,811		119,963
Total	$	669,633	$	409,169

XML 24 R13.htm IDEA: XBRL DOCUMENT

PREFERRED STOCK REDEMPTION	3 Months Ended
PREFERRED STOCK REDEMPTION	Jan. 31, 2018
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	6. PREFERRED STOCK REDEMPTION On November 11, 2016, the holder of all our outstanding Series A Preferred Stock (the “Series A Preferred”) with an aggregate stated value of $3,500,000 exercised its right of redemption to receive such amount from proceeds from the sale of the Company’s equity securities. On December 6, 2016, we entered into an agreement with the holder of the Series A Preferred setting forth the terms under which such redemption would take place (the “Series A Redemption Terms”). Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which was due on or before June 1, 2017 and the remainder of which was due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”). The Redemption Debenture was secured by a lien on the Company’s assets and prohibited the Company from incurring any senior indebtedness other than equipment financing in connection with the Company’s business. The Redemption Debenture was paid in full during fiscal year 2017. The difference between the fair value of the consideration given to the holder of our Series A Preferred and the carrying value of the Series A Preferred represents a return to the preferred shareholder which is treated in a similar manner as that of dividends paid on preferred stock. In the redemption, the Series A Preferred holder received $500,000 in cash, the Redemption Debenture with a present value of approximately $2,999,000 and the Redemption Warrant with a fair value of approximately $2,801,000, determined using the Black Scholes pricing model, and waived the Series A Preferred’s conversion right with an intrinsic value of approximately $792,000, resulting in total consideration given to the Series A Preferred holder of approximately $5,508,000. The difference between the fair value of the consideration and the $3,500,000 carrying value of the Series A Preferred resulted in a deemed dividend to the Series A Preferred holder of approximately $2,008,000.

XML 25 R14.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE OF COMMON STOCK	3 Months Ended
NET INCOME (LOSS) PER SHARE OF COMMON STOCK	Jan. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	7. NET INCOME (LOSS) PER SHARE OF COMMON STOCK Basic net income (loss) per common share (“Basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted net income (loss) per common share (“Diluted EPS”) is computed by dividing net income (loss) by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. The treasury stock method reduces the dilutive effect of potentially dilutive securities as it assumes that any cash proceeds (from the issuance of potentially dilutive securities) are used to buy back shares at the average share price during the period. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the three months ended January 31, 2018 and 2017, were stock options to purchase 3,458,846 and 3,162,272 shares, respectively, and warrants to purchase 829,400 and 837,405 shares, respectively.

XML 26 R15.htm IDEA: XBRL DOCUMENT

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	3 Months Ended
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	Jan. 31, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	8. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers. This amendment updates addressing revenue from contracts with customers, which clarifies existing accounting literature relating to how and when a company recognizes revenue. Under the standard, a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. This standard update is effective for interim and annual reporting periods beginning after December 15, 2016, and were to be applied retrospectively or the cumulative effect as of the date of adoption, with early application not permitted. In July 2015, a one-year deferral of the effective date of the new guidance was approved. We do not expect the adoption of ASU 2014-09 to have a material impact on our consolidated financial statements and related disclosures. In November 2015, the FASB issued Accounting Standards Update 2015-17 (“ASU 2015-17”) to simplify the presentation of deferred taxes. This amendment requires that all deferred tax assets and liabilities, along with any related valuation allowances, be classified as noncurrent on the balance sheet. Adoption of this standard is required for annual periods beginning after December 15, 2016. The adoption of this amendment did not have an impact on our consolidated financial statements and related disclosures as we currently do not present deferred tax assets or liabilities. In February 2016, the FASB issued Accounting Standards Update 2016-02 (“ASU 2016-02”) which requires lessees to recognize most leases on the balance sheet. This is expected to increase both reported assets and liabilities. The new lease standard does not substantially change lessor accounting. For public companies, the standard will be effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption is permitted. Lessees and lessors will be required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance, using a modified retrospective transition method. The requirements of this standard include a significant increase in required disclosures. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is currently ongoing. In March 2016, the FASB issued Accounting Standards Update 2016-09 (“ASU 2016-09”) that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election for forfeitures as they occur. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those years. We adopted ASU 2016-09 on November 1, 2017 and the adoption did not have an impact on our consolidated financial statements and related disclosures. In May 2017, the FASB issued Accounting Standards Update 2017-09 (“ASU 2017-09”) that provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting. This update is effective for all entities for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. We began a detailed assessment of the impact that this guidance will have on our consolidated financial statements and related disclosures, and our analysis is ongoing.

XML 27 R16.htm IDEA: XBRL DOCUMENT

INCOME TAXES	3 Months Ended
INCOME TAXES	Jan. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	9. INCOME TAXES We file Federal, New York, California and Pennsylvania state income tax returns. Due to net operating losses, the statute of limitations for Federal and New York State income tax returns remains open to examination by taxing authorities since the fiscal year ended October 31, 1998. We account for interest and penalties related to income tax matters, if any, in general and administrative expenses. There are no unrecognized income tax benefits as of January 31, 2018 and October 31, 2017. We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have substantial net operating loss carryforwards for Federal, New York State and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets.

XML 28 R17.htm IDEA: XBRL DOCUMENT

COMMITMENT AND CONTINGENCES	3 Months Ended
COMMITMENT AND CONTINGENCES	Jan. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	10. COMMITMENT AND CONTINGENCES Litigation Matters Other than suits we bring to enforce our patent rights we are not a party to any material pending legal proceedings other than that which arise in the ordinary course of business. We believe that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on our financial position or results of operations.

XML 29 R18.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING (Tables)

3 Months Ended

Jan. 31, 2018

Accounting Policies [Abstract]

Schedule of Variable Interest Entities [Table Text Block]

Balance October 31, 2017	$	0
Issuance of noncontrolling interest in Certainty		(4,318)
Net loss attributable to noncontrolling interest		(27,402)
Balance January 31, 2018	$	(31,720)

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Tables)

3 Months Ended

Jan. 31, 2018

2003 Share Plan [Member]

STOCK BASED COMPENSATION (Tables) [Line Items]

Share-based Compensation, Stock Options, Activity [Table Text Block]

		Weighted Average Exercise Price Per Share
				Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	30,600	$	3.16
Exercised	(10,600)	$	0.67
Forfeited	(5,600)	$	3.63
Options Outstanding and exercisable at January 31, 2018	14,400	$	4.81	$	17,280

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$ 0.67 - $17.50	14,400	1.31	$	4.81
				.

2010 Share Plan [Member]

STOCK BASED COMPENSATION (Tables) [Line Items]

Share-based Compensation, Stock Options, Activity [Table Text Block]

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	1,637,246	$	1.50
Granted	50,000	$	2.30
Exercised	(18,000)	$	0.67
Forfeited	(4,800)	$	3.80
Options Outstanding at January 31, 2018	1,664,446	$	1.52	$	3,752,696
Options Exercisable at January 31, 2018	1,013,106	$	1.72	$	2,120,876

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

	Options Outstanding				Options Exercisable
		Weighted Average Remaining Contractual Life (in years)				Weighted Average Remaining Contractual Life (in years)
								Weighted Average Exercise Price
				Weighted Average Exercise Price
Range of Exercise Prices	Number Outstanding				Number Exercisable
Range of Exercise Prices	Number Outstanding				Number Exercisable

$0.67	983,000	7.40	$	0.67	556,754	6.18	$	0.67
$ 2.27 - $ 7.00	681,446	6.00	$	2.75	456,352	4.61	$	2.99

Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]

STOCK BASED COMPENSATION (Tables) [Line Items]

Share-based Compensation, Stock Options, Activity [Table Text Block]

		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value

	Shares
Options Outstanding at October 31, 2017	1,780,000	$	1.58
Options Outstanding and exercisable at January 31, 2018	1,780,000	$	1.58	$	3,953,820

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

	Number Outstanding and Exercisable	Weighted Average Remaining Contractual Life (in years)
				Weighted Average Exercise Price
Range of Exercise Prices
Range of Exercise Prices
$0.67	1,046,000	4.66	$	0.67
$ 2.58-$ 5.56	734,000	4.11	$	2.88

XML 31 R20.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Jan. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	2,470,624	$	-	$	-	$	2,470,624
Certificates of deposit – Short-term investments		-		2,650,000		-		2,650,000
Total financial assets	$	2,470,624	$	2,650,000	$	-	$	5,120,624

	Level 1		Level 2		Level 3		Total

Money market funds – Cash equivalents	$	3,079,282	$	-	$	-	$	3,079,282
Certificates of deposit – Short term investments		-		3,500,000		-		3,500,000
Total financial assets	$	3,079,282	$	3,500,000	$	-	$	6,579,232

XML 32 R21.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Tables)

3 Months Ended

Jan. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	January 31, 2018		October 31, 2017
	January 31, 2018		October 31, 2017
Accrued severance costs		161,475		237,563
Payroll and related expenses		178,916		51,643
Accrued collaborative research and license expenses		220,431		-
Accrued other		108,811		119,963
Total	$	669,633	$	409,169

XML 33 R22.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING (Details) - USD ($)	3 Months Ended
BUSINESS AND FUNDING (Details) - USD ($)	Jan. 31, 2018	Jan. 31, 2017	Oct. 31, 2017
Accounting Policies [Abstract]
Net Cash Provided by (Used in) Operating Activities	$ (1,339,993)	$ (729,913)
Net Cash Provided by (Used in) Investing Activities	847,482	135,879
Payments to Acquire Short-term Investments	1,250,000
Proceeds from Sale of Short-term Investments	2,100,000	150,000
Payments to Acquire Property, Plant, and Equipment	2,518	14,121
Cash, Period Increase (Decrease)	1,342,000
Cash, Cash Equivalents, and Short-term Investments	5,497,000		$ 6,839,000
Amortization of Intangible Assets	$ 81,324	$ 81,324

XML 34 R23.htm IDEA: XBRL DOCUMENT

BUSINESS AND FUNDING (Details) - Changes in noncontrolling interest - USD ($)	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Changes in noncontrolling interest [Abstract]
Balance October 31, 2017	$ 0
Issuance of noncontrolling interest in Certainty	64,656
Net loss attributable to noncontrolling interest	(27,402)
Balance January 31, 2018	$ (31,720)

XML 35 R24.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - USD ($)	3 Months Ended
STOCK BASED COMPENSATION (Details) - USD ($)	Jan. 31, 2018	Jan. 31, 2017
STOCK BASED COMPENSATION (Details) [Line Items]
Proceeds from Stock Options Exercised (in Dollars)		$ 5,665
2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 2.30
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	18,000
Employee Stock Option [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation (in Dollars)	$ 214,000	$ 260,000
Employee Stock Option [Member] \| 2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000	106,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 2.30	$ 5.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	28,600	2,200
Proceeds from Stock Options Exercised (in Dollars)	$ 0	$ 6,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Withheld in Connection with Cashless Exercises	5,515	0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	802,450
Employee Stock Option [Member] \| Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,780,000
Employee Stock Option [Member] \| Minimum [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Employee Stock Option [Member] \| Maximum [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Employee Stock Option [Member] \| Consultant [Member]
STOCK BASED COMPENSATION (Details) [Line Items]
Share-based Compensation (in Dollars)	$ 53,000	$ 0
Stock Issued During Period, Shares, Issued for Services	5,347	3,463
Consultation Expense (in Dollars)	$ 15,000	$ 18,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan - 2003 Share Plan [Member]	3 Months Ended
	Jan. 31, 2018 USD ($) $ / shares shares
STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan [Line Items]
Options Outstanding at October 31, 2017 \| shares	30,600
Options Outstanding at October 31, 2017 \| $ / shares	$ 3.16
Exercised \| shares	(10,600)
Exercised \| $ / shares	$ 0.67
Forfeited \| shares	(5,600)
Forfeited \| $ / shares	$ 3.63
Options Outstanding and exercisable at January 31, 2018 \| shares	14,400
Options Outstanding and exercisable at January 31, 2018 \| $ / shares	$ 4.81
Options Outstanding and exercisable at January 31, 2018 \| $	$ 17,280

XML 37 R26.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2003 Share Plan - 2003 Share Plan [Member] - Range Of Exercise Prices $0.67 To $17.50 [Member]	3 Months Ended
	Jan. 31, 2018 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	14,400
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	1 year 113 days
Options Outstanding and Exercisable, Weighted Average Exercise Price \| $ / shares	$ 4.81

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan - 2010 Share Plan [Member]	3 Months Ended
	Jan. 31, 2018 USD ($) $ / shares shares
STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan [Line Items]
Options Outstanding at October 31, 2017 \| shares	1,637,246
Options Outstanding at October 31, 2017 \| $ / shares	$ 1.50
Granted \| shares	50,000
Granted \| $ / shares	$ 2.30
Exercised \| shares	(18,000)
Exercised \| $ / shares	$ 0.67
Forfeited \| shares	(4,800)
Forfeited \| $ / shares	$ 3.80
Options Outstanding at January 31, 2018 \| shares	1,664,446
Options Outstanding at January 31, 2018 \| $ / shares	$ 1.52
Options Outstanding at January 31, 2018 \| $	$ 3,752,696
Options Exercisable at January 31, 2018 \| shares	1,013,106
Options Exercisable at January 31, 2018 \| $ / shares	$ 1.72
Options Exercisable at January 31, 2018 \| $	$ 2,120,876

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2010 Share Plan - 2010 Share Plan [Member]	3 Months Ended
	Jan. 31, 2018 $ / shares shares
Range Of Exercise Prices $0.67 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number \| shares	983,000
Options Outstanding,Weighted Average Remaining Contractual Life	7 years 146 days
Options Outstanding, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 0.67
Options Exercisable, Number \| shares	556,754
Options Exercisable,Weighted Average Remaining Contractual Life	6 years 65 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 0.67
Range Of Exercise Prices $2.27 To $7.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number \| shares	681,446
Options Outstanding,Weighted Average Remaining Contractual Life	6 years
Options Outstanding, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 2.75
Options Exercisable, Number \| shares	456,352
Options Exercisable,Weighted Average Remaining Contractual Life	4 years 222 days
Options Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 2.99

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan - Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member] - USD ($)	Jan. 31, 2018	Oct. 31, 2017
STOCK BASED COMPENSATION (Details) - Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan [Line Items]
Options Outstanding at October 31, 2017		1,780,000
Options Outstanding at October 31, 2017		$ 1.58
Options Outstanding and exercisable at January 31, 2018	1,780,000
Options Outstanding and exercisable at January 31, 2018	$ 1.58
Options Outstanding and exercisable at January 31, 2018	$ 3,953,820

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable not granted under the 2003 Share Plan or the 2010 Share Plan - Stock Options Not Granted Under 2003 Share Plan Or 2010 Share Plan [Member]	3 Months Ended
	Jan. 31, 2018 $ / shares shares
Range Of Exercise Prices $0.67 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	1,046,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	4 years 240 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 0.67
Range Of Exercise Prices $2.58 To $5.56 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding and Exercisable, Number \| shares	734,000
Options Outstanding and Exercisable, Weighted Average Remaining Contractual Life	4 years 40 days
Options Outstanding and Exercisable, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 2.88

XML 42 R31.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value - USD ($)	Jan. 31, 2018	Oct. 31, 2017
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	$ 5,120,624	$ 6,579,232
Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,470,624	3,079,282
Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,650,000	3,500,000
Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Cash Equivalents [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,470,624	3,079,282
Cash Equivalents [Member] \| Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,470,624	3,079,282
Cash Equivalents [Member] \| Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Cash Equivalents [Member] \| Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Certificates of Deposit [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,650,000	3,500,000
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 1 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets	2,650,000	3,500,000
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 3 [Member]
FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value [Line Items]
Financial assets

XML 43 R32.htm IDEA: XBRL DOCUMENT

SHORT-TERM INVESTMENTS (Details) - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Investments Schedule [Abstract]
Certificates of Deposit, at Carrying Value	$ 2,650,000	$ 3,500,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Details) - Accrued liabilities - USD ($)	Jan. 31, 2018	Oct. 31, 2017
Accrued liabilities [Abstract]
Accrued severance costs	$ 161,475	$ 237,563
Payroll and related expenses	178,916	51,643
Accrued collaborative research and license expenses	220,431
Accrued other	108,811	119,963
Total	$ 669,633	$ 409,169

XML 45 R34.htm IDEA: XBRL DOCUMENT

PREFERRED STOCK REDEMPTION (Details) - USD ($)			3 Months Ended
PREFERRED STOCK REDEMPTION (Details) - USD ($)	Dec. 09, 2016	Dec. 06, 2016	Jan. 31, 2018	Nov. 11, 2016
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Preferred Stock, Redemption Amount				$ 3,500,000
Preferred Stock, Redemption Terms		Pursuant to the Series A Redemption Terms, on December 9, 2016 the holder of the Series A Preferred received (i) $500,000 in cash, (ii) a 12% secured debenture evidencing the remaining $3,000,000 amount to be redeemed, $1,000,000 of which was due on or before June 1, 2017 and the remainder of which was due November 11, 2017 (the “Redemption Debenture”), and (iii) a 5 year warrant to purchase 500,000 shares of the Company’s common stock at an exercise price equal to 10% below the thirty (30) day volume weighted average closing price of our common stock at closing (the “Redemption Warrant”).
Payments for Repurchase of Redeemable Convertible Preferred Stock	$ 500,000
Warrant Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	500,000
Warrant Exercise Price Percentage	10.00%
Redemption Debenture Present Value			$ 2,999,000
Preferred Stock Conversion Right Intrinsic Value			792,000
Preferred Holder Consideration Transferred			5,508,000
Redeemable Preferred Stock Dividends			2,008,000
Due On Or Before June1 2017 [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Debt Instrument, Face Amount	$ 1,000,000
Redemption Warrant [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 2,801,000
Redemption Debenture [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Secured Debt	$ 3,000,000
Secured Debt [Member]
PREFERRED STOCK REDEMPTION (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%

XML 46 R35.htm IDEA: XBRL DOCUMENT

NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) - shares	3 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Employee Stock Option [Member]
NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,458,846	3,162,272
Warrant [Member]
NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	829,400	837,405

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 92 154 1 false 31 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.ITUScorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.ITUScorp.com/role/ConsolidatedBalanceSheet CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.ITUScorp.com/role/ConsolidatedBalanceSheet_Parentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.ITUScorp.com/role/ConsolidatedIncomeStatement CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) Sheet http://www.ITUScorp.com/role/ConsolidatedIncomeStatement_Parentheticals CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) Sheet http://www.ITUScorp.com/role/ShareholdersEquityType2or3 CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) Statements 6 false false R7.htm 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.ITUScorp.com/role/ConsolidatedCashFlow CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 007 - Disclosure - BUSINESS AND FUNDING Sheet http://www.ITUScorp.com/role/BUSINESSANDFUNDING BUSINESS AND FUNDING Notes 8 false false R9.htm 008 - Disclosure - STOCK BASED COMPENSATION Sheet http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATION STOCK BASED COMPENSATION Notes 9 false false R10.htm 009 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 10 false false R11.htm 010 - Disclosure - SHORT-TERM INVESTMENTS Sheet http://www.ITUScorp.com/role/SHORTTERMINVESTMENTS SHORT-TERM INVESTMENTS Notes 11 false false R12.htm 011 - Disclosure - ACCRUED EXPENSES Sheet http://www.ITUScorp.com/role/ACCRUEDEXPENSES ACCRUED EXPENSES Notes 12 false false R13.htm 012 - Disclosure - PREFERRED STOCK REDEMPTION Sheet http://www.ITUScorp.com/role/PREFERREDSTOCKREDEMPTION PREFERRED STOCK REDEMPTION Notes 13 false false R14.htm 013 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK Sheet http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCK NET INCOME (LOSS) PER SHARE OF COMMON STOCK Notes 14 false false R15.htm 014 - Disclosure - EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS Sheet http://www.ITUScorp.com/role/EFFECTOFRECENTLYADOPTEDANDISSUEDPRONOUNCEMENTS EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS Notes 15 false false R16.htm 015 - Disclosure - INCOME TAXES Sheet http://www.ITUScorp.com/role/INCOMETAXES INCOME TAXES Notes 16 false false R17.htm 016 - Disclosure - COMMITMENT AND CONTINGENCES Sheet http://www.ITUScorp.com/role/COMMITMENTANDCONTINGENCES COMMITMENT AND CONTINGENCES Notes 17 false false R18.htm 017 - Disclosure - BUSINESS AND FUNDING (Tables) Sheet http://www.ITUScorp.com/role/BUSINESSANDFUNDINGTables BUSINESS AND FUNDING (Tables) Tables http://www.ITUScorp.com/role/BUSINESSANDFUNDING 18 false false R19.htm 018 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables STOCK BASED COMPENSATION (Tables) Tables http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATION 19 false false R20.htm 019 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTS 20 false false R21.htm 020 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.ITUScorp.com/role/ACCRUEDEXPENSESTables ACCRUED EXPENSES (Tables) Tables http://www.ITUScorp.com/role/ACCRUEDEXPENSES 21 false false R22.htm 021 - Disclosure - BUSINESS AND FUNDING (Details) Sheet http://www.ITUScorp.com/role/BUSINESSANDFUNDINGDetails BUSINESS AND FUNDING (Details) Details http://www.ITUScorp.com/role/BUSINESSANDFUNDINGTables 22 false false R23.htm 022 - Disclosure - BUSINESS AND FUNDING (Details) - Changes in noncontrolling interest Sheet http://www.ITUScorp.com/role/ChangesinnoncontrollinginterestTable BUSINESS AND FUNDING (Details) - Changes in noncontrolling interest Details http://www.ITUScorp.com/role/BUSINESSANDFUNDINGTables 23 false false R24.htm 023 - Disclosure - STOCK BASED COMPENSATION (Details) Sheet http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONDetails STOCK BASED COMPENSATION (Details) Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 24 false false R25.htm 024 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan Sheet http://www.ITUScorp.com/role/Informationregardingthe2003SharePlanTable STOCK BASED COMPENSATION (Details) - Information regarding the 2003 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 25 false false R26.htm 025 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2003 Share Plan Sheet http://www.ITUScorp.com/role/Stockoptionsoutstandingandexercisableunderthe2003SharePlanTable STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2003 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 26 false false R27.htm 026 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan Sheet http://www.ITUScorp.com/role/Informationregardingthe2010SharePlanTable STOCK BASED COMPENSATION (Details) - Information regarding the 2010 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 27 false false R28.htm 027 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2010 Share Plan Sheet http://www.ITUScorp.com/role/Stockoptionsoutstandingandexercisableunderthe2010SharePlanTable STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable under the 2010 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 28 false false R29.htm 028 - Disclosure - STOCK BASED COMPENSATION (Details) - Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan Sheet http://www.ITUScorp.com/role/Informationregardingstockoptionsoutstandingthatwerenotgrantedunderthe2003Planorthe2010PlanTable STOCK BASED COMPENSATION (Details) - Information regarding stock options outstanding that were not granted under the 2003 Plan or the 2010 Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 29 false false R30.htm 029 - Disclosure - STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable not granted under the 2003 Share Plan or the 2010 Share Plan Sheet http://www.ITUScorp.com/role/Stockoptionsoutstandingandexercisablenotgrantedunderthe2003SharePlanorthe2010SharePlanTable STOCK BASED COMPENSATION (Details) - Stock options outstanding and exercisable not granted under the 2003 Share Plan or the 2010 Share Plan Details http://www.ITUScorp.com/role/STOCKBASEDCOMPENSATIONTables 30 false false R31.htm 030 - Disclosure - FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value Sheet http://www.ITUScorp.com/role/HierarchyforfinancialassetsmeasuredatfairvalueTable FAIR VALUE MEASUREMENTS (Details) - Hierarchy for financial assets measured at fair value Details http://www.ITUScorp.com/role/FAIRVALUEMEASUREMENTSTables 31 false false R32.htm 031 - Disclosure - SHORT-TERM INVESTMENTS (Details) Sheet http://www.ITUScorp.com/role/SHORTTERMINVESTMENTSDetails SHORT-TERM INVESTMENTS (Details) Details http://www.ITUScorp.com/role/SHORTTERMINVESTMENTS 32 false false R33.htm 032 - Disclosure - ACCRUED EXPENSES (Details) - Accrued liabilities Sheet http://www.ITUScorp.com/role/AccruedliabilitiesTable ACCRUED EXPENSES (Details) - Accrued liabilities Details http://www.ITUScorp.com/role/ACCRUEDEXPENSESTables 33 false false R34.htm 033 - Disclosure - PREFERRED STOCK REDEMPTION (Details) Sheet http://www.ITUScorp.com/role/PREFERREDSTOCKREDEMPTIONDetails PREFERRED STOCK REDEMPTION (Details) Details http://www.ITUScorp.com/role/PREFERREDSTOCKREDEMPTION 34 false false R35.htm 034 - Disclosure - NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) Sheet http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCKDetails NET INCOME (LOSS) PER SHARE OF COMMON STOCK (Details) Details http://www.ITUScorp.com/role/NETINCOMELOSSPERSHAREOFCOMMONSTOCK 35 false false All Reports Book All Reports itus-20180131.xml itus-20180131.xsd itus-20180131_cal.xml itus-20180131_def.xml itus-20180131_lab.xml itus-20180131_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 53 0001513162-18-000062-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001513162-18-000062-xbrl.zip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�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ɍ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end